For the quarter ending 2025-09-30, VIR made $240,000 in revenue. -$163,141,000 in net income. Net profit margin of -67975.42%.
| Income Statement | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 |
|---|---|---|---|---|
| Total revenues | 240,000 | 1,214,000 | 3,032,000 | 29,128,500 |
| Cost of revenue | -11,000 | - | - | - |
| Research and development | 151,463,000 | 97,509,000 | 118,645,000 | 103,104,000 |
| Selling, general and administrative | 22,231,000 | 22,283,000 | 23,944,000 | 31,511,000 |
| Restructuring, long-lived assets impairment and related charges, net | 0 | -172,000 | -10,000 | -1,996,000 |
| Cost of revenue | - | 11,000 | - | 371,500 |
| Total operating expenses | 173,683,000 | 119,631,000 | 142,579,000 | 138,237,000 |
| Loss from operations | -173,443,000 | -118,417,000 | -139,547,000 | -98,615,500 |
| Change in fair value of equity investments | 1,335,000 | -3,382,000 | 6,382,000 | -3,543,500 |
| Interest income | 9,363,000 | 10,785,000 | 12,288,000 | 18,094,000 |
| Other expense, net | -228,000 | 226,000 | -72,000 | -396,500 |
| Total other income | 10,470,000 | 7,629,000 | 18,598,000 | 13,778,000 |
| Loss before (provision for) benefit from income taxes | -162,973,000 | -110,788,000 | -120,949,000 | -84,837,500 |
| (provision for) benefit from income taxes | 168,000 | 170,000 | 16,000 | 95,000 |
| Net (loss) income | - | - | - | -84,932,500 |
| Net loss | -163,141,000 | -110,958,000 | -120,965,000 | -84,932,500 |
| Net loss per share, basic (in usd per share) | -1.17 | -0.8 | -0.88 | -0.625 |
| Net loss per share, diluted (in usd per share) | -1.17 | -0.8 | -0.88 | -0.625 |
| Weighted-average shares outstanding, basic (in shares) | 138,930,173 | 138,447,469 | 137,468,900 | -68,320,306.5 |
| Weighted-average shares outstanding, diluted (in shares) | 138,930,173 | 138,447,469 | 137,468,900 | -68,320,306.5 |
Vir Biotechnology, Inc. (VIR)
Vir Biotechnology, Inc. (VIR)